Missed Opportunities for Hepatitis C Testing in Opioid Treatment Programs.

• Autores: Jemima A. Frimpong
• Localización: American journal of public health, ISSN 0090-0036, Vol. 103, Nº. 6, 2013, págs. 1028-1030
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • HCV has surpassed HIV as a cause of death in the United States and is particularly prevalent among injection drug users. I examined the availability of on-site HCV testing in a nationally representative sample of opioid treatment programs. Nearly 68% of these programs had the staff required for HCV testing, but only 34% offered on-site testing. Availability of on-site testing increased only slightly with the proportion of injection drug users among clients. The limited HCV testing services in opioid treatment programs is a key challenge to reducing HCV in the US population. [ABSTRACT FROM AUTHOR]